StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SAMRATPH.BO$212.55-14.60%
Fair $212.55+0.0%

SAMRATPH.BO

Samrat Pharmachem Limited

Basic Materials / ChemicalsBSE

$212.55

-36.35 (-14.60%)

Fairly Valued+0.0%Fair Value $212.55Fund rank 27/100 · Data gapFallback financials|
SA 54/C
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-106.0M · quality 46.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 16/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

54/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists.
Thesis & Journal · SAMRATPH.BOLocal privado en este navegador · Samrat Pharmachem Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$657M

P/E

9.2x

↓

EV/EBITDA

6.9x

↓

ROE

9.9%

↑

Gross Margin

5.3%

↓

Debt/Equity

0.14

↓
52-Week Range$213
$190$420

TradingView lightweight chart

SAMRATPH.BO price, volumen y niveles de valoración

Último $212.55Periodo +4151.0%
Fair value: $212.55

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+8.8%

FCF CAGR

—

FCF margin

-3.7%

FCF / Net income

-1.49x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.86B · net income $71.1M · FCF $-106.0M

2022-FY → 2025-FY

Gross margin

5.3%-7.3% pts

Operating margin

3.4%-7.3% pts

Net margin

2.5%-5.3% pts

FCF margin

-3.7%-11.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.86B$2.86B$2.82B$3.11B$2.22B
Net Income$71.1M$71.1M$21.6M$166.3M$171.8M
EBITDA$110.3M$110.3M$37.2M$241.0M$245.6M
EPS23.0223.027.0053.8355.62
Gross Margin5.3%5.3%2.7%9.3%12.7%
Operating Margin3.4%3.4%0.7%7.5%10.7%
Net Margin2.5%2.5%0.8%5.4%7.7%
Balance Sheet
Debt/Equity0.140.140.130.300.16
Cash Flow
Free Cash Flow$-106.0M$-106.0M$87.5M$-109.0M$162.0M
Returns
ROE9.9%9.9%3.3%26.3%36.7%
Valuation
P/E9.239.2352.717.989.19
EV/EBITDA6.856.8530.335.796.14
P/B0.910.911.752.103.37
Growth & Yield
Revenue Growth1.5%1.5%-9.4%40.1%—
EPS Growth228.9%228.9%-87.0%-3.2%—
Dividend Yield0.4%0.4%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-6.4%

fácil

EPS terminal req.

$18.86

Spread vs growth

235.3%

5Y implied EPS CAGR

-0.2%

fácil

EPS terminal req.

$22.82

Spread vs growth

229.0%

10Y implied EPS CAGR

4.8%

fácil

EPS terminal req.

$36.75

Spread vs growth

224.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -42.2%

Total return

-42.2%

Start / end P/E

52.9x → 9.2x

EPS bridge

7.00 → 23.02

Residual

-188.9%

EPS growth+228.9%
Multiple rerating-82.5%
Dividend+0.4%
Residual / FX / buybacks / cross-term-188.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.